Oğuzhan Işılay on Stabilizing Human Blood Clotting Factor VIII
Oğuzhan Işılay, Bioinformatics Intern at Mersin Üniversity, shared on LinkedIn:
”I recently read and analyzed an interesting research paper on stabilizing Human Blood Clotting Factor VIII (FVIII) using proteins derived from tardigrades.
FVIII is a critical therapeutic protein used in the treatment of Hemophilia A, but it is highly unstable and requires strict cold-chain storage.
This creates major logistical and economic challenges, especially in low-resource settings.
The study explored whether proteins associated with desiccation tolerance in tardigrades (such as CAHS and SAHS proteins) could protect FVIII during repeated drying and rehydration cycles.
Remarkably, some tardigrade proteins preserved FVIII activity significantly better than commonly used stabilizers like trehalose, even after multiple stress cycles.
What I found particularly interesting is the broader implication: bio-inspired stabilization strategies could reduce cold-chain dependency and improve global access to protein-based therapeutics.
This analysis reinforced how concepts from extremophile biology can be directly translated into real-world biotechnological and medical solutions.
Reference.”
Read the full article here.
Article: Natural and engineered mediators of desiccation tolerance stabilize Human Blood Clotting Factor VIII in a dry state
Authors: Maxwell H. Packebush, Silvia Sanchez-Martinez, Sourav Biswas, Shraddha KC, Kenny H. Nguyen, John F. Ramirez, Vincent Nicholson, Thomas C. Boothby
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 23, 2026, 15:36Simon Senanu: The Peripheral Blood Smear as an Essential Diagnostic Tool in Modern Medicine
-
Feb 23, 2026, 15:32Cheng-Hock Toh: The Paradox of Hematology
-
Feb 23, 2026, 15:20Rabab Al Dawood: Moderating the Coagulation and Hemostasis Session at the ISLH 1st Joint Conference
-
Feb 23, 2026, 15:16Amira Khater: Key Updates on Pulmonary Embolism Management from AHA and ACC Guidelines
-
Feb 23, 2026, 14:45Stacey McGeown: Rare Disease Awareness Day at QUB Marks the Start of Rare Disease Month
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline